We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Correlation of PET-CT Studies With Serum Protein Analysis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00547742
First Posted: October 23, 2007
Last Update Posted: July 20, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Stanford University
  Purpose
To correlate serum proteomics patterns with PET/CT findings to improve cancer diagnosis, staging, prognosis, and therapy monitoring.

Condition Intervention
Carcinomas (Including Squamous Cell and Adenocarcinoma) Procedure: PET/CT Scan Procedure: phlebotomy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Correlation of PET-CT Studies With Serum Protein Analysis

Further study details as provided by Stanford University:

Biospecimen Retention:   Samples Without DNA
blood

Estimated Enrollment: 1500
Study Start Date: July 2005
Study Completion Date: June 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients having PET/CT scans
Criteria

Inclusion Criteria:1. Patients must have a PET/CT study performed at the time of blood collection.

2. Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them.

Exclusion Criteria:1. Patients who are not eligible for a PET/CT study.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00547742


Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Dr Andrew Quon Stanford University
  More Information

Responsible Party: Dr Andrew Quon, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT00547742     History of Changes
Other Study ID Numbers: VAR0011
96184
First Submitted: October 19, 2007
First Posted: October 23, 2007
Last Update Posted: July 20, 2010
Last Verified: July 2010

Additional relevant MeSH terms:
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms